Role of Endocrine Function of Adipose Tissue in the Development of Chronic Obstructive Pulmonary Disease: a Review of Recent Advances

doi:10.12114/j.issn.1007-9572.2022.0541

Abstract

Abstract:

In addition to affecting adjacent tissues and organs through its mechanical characteristics or mechanical functions, adipose tissue participates in the development of a variety of obesity-related diseases by effectively establishing an interaction information network with organs of the respiratory system and other remote organs through signaling pathways of adipokines secreted by adipocytes. As a breakthrough in the field of endocrinology, the endocrine function of adipose tissue has attracted increasing attention in life sciences. A number of recent epidemiological studies have revealed that obesity is an important risk factor for chronic obstructive pulmonary disease and other respiratory impairments. We reviewed recent advances in the role of adiponectin, leptin, endolipin and other adipocytokines in the development of COPD, providing new ideas for the prevention and treatment of COPD from the perspective of endocrine function of adipose tissue.

Key words: Pulmonary disease, chronic obstructive, Obesity, Adipose tissue, Endocrine function, Mechanism research

摘要：

脂肪组织除了通过其力学特征或机械功能对周边组织器官产生影响以外，还可以凭借非物理性的内分泌功能通过脂肪因子输出信号方式有效地建立起与呼吸系统等远程器官的互作信息网络，进而参与多种肥胖相关疾病的发生与发展。作为内分泌领域的突破性进展之一，脂肪组织的内分泌功能受到生命科学领域的关注。近年来，多项流行病调查研究揭示了肥胖是造成慢性阻塞性肺疾病（COPD）等呼吸系统疾病肺功能损害重要的危险因素。基于此，本文将分别梳理脂联素、瘦素、内脂素等脂肪因子在COPD中的作用机制，从脂肪组织内分泌功能角度为COPD的防治研究提供新思路。

关键词: 肺疾病, 慢性阻塞性, 肥胖, 脂肪组织, 内分泌功能, 机制研究

WANG Yide,LI Zheng,LI Fengsen. Role of Endocrine Function of Adipose Tissue in the Development of Chronic Obstructive Pulmonary Disease: a Review of Recent Advances[J]. Chinese General Practice, 2023, 26(06): 754-759. DOI: 10.12114/j.issn.1007-9572.2022.0541.
王益德,李争,李风森. 从脂肪组织的内分泌功能角度探讨其在慢性阻塞性肺疾病中的作用机制研究[J]. 中国全科医学, 2023, 26(06): 754-759. DOI: 10.12114/j.issn.1007-9572.2022.0541.

References 66

[1]	HALL J E, DO CARMO J M, DA SILVA A A，et al. Obesity，kidney dysfunction and hypertension：mechanistic links[J]. Nat Rev Nephrol，2019，15(6):367-385. DOI：10.1038/s41581-019-0145-4.
[2]	JAACKS L M, VANDEVIJVERE S, PAN A，et al. The obesity transition：stages of the global epidemic[J]. Lancet Diabetes Endocrinol，2019，7(3):231-240. DOI：10.1016/S2213-8587(19)30026-9.
[3]	BRAZZALE D J, PRETTO J J, SCHACHTER L M. Optimizing respiratory function assessments to elucidate the impact of obesity on respiratory health[J]. Respirology，2015，20(5):715-721. DOI：10.1111/resp.12563.
[4]	LIN C K, LIN C C. Work of breathing and respiratory drive in obesity[J]. Respirology，2012，17(3):402-411. DOI：10.1111/j.1440-1843.2011.02124.x.
[5]	ROBINSON P D. Obesity and its impact on the respiratory system[J]. Paediatr Respir Rev，2014，15(3):219-226. DOI：10.1016/j.prrv.2014.06.003.
[6]	KIM H J, PARK J H, MIN J Y，et al. Abdominal adiposity intensifies the negative effects of ambient air pollution on lung function in Korean men[J]. Int J Obes （Lond），2017，41(8):1218-1223. DOI：10.1038/ijo.2017.97.
[7]	SORLÍ-AGUILAR M, MARTÍN-LUJÁN F, FLORES-MATEO G，et al. Adiposity markers and lung function in smokers：a cross-sectional study in a Mediterranean population[J]. BMC Pulm Med，2016，16(1):178. DOI：10.1186/s12890-016-0341-y.
[8]	DIXON A E, PETERS U. The effect of obesity on lung function[J]. Expert Rev Respir Med，2018，12(9):755-767. DOI：10.1080/17476348.2018.1506331.
[9]	BORIEK A M, LOPEZ M A, VELASCO C，et al. Obesity modulates diaphragm curvature in subjects with and without COPD[J]. Am J Physiol Regul Integr Comp Physiol，2017，313(5):R620-629. DOI：10.1152/ajpregu.00173.2017.
[10]	RODRIGUES G C, ROCHA N N, MAIA L A，et al. Impact of experimental obesity on diaphragm structure，function，and bioenergetics[J]. J Appl Physiol （1985），2020，129(5):1062-1074. DOI：10.1152/japplphysiol.00262.2020.
[11]	曲伸，朱冰. 从代谢角度认识肥胖，用整体策略管理肥胖——近期国内外肥胖观点的理解与解析[J]. 中华内分泌代谢杂志，2018，34(4):269-273. DOI：10.3760/cma.j.issn.1000-6699.2018.04.001.
[12]	王益德，李争，李风森. 脂肪酸结合蛋白4与慢性阻塞性肺疾病关系研究进展[J]. 现代医学，2020，48(11):1490-1494.
[13]	SIITERI P K. Adipose tissue as a source of hormones[J]. Am J Clin Nutr，1987，45(1 Suppl):277-282. DOI：10.1093/ajcn/45.1.277.
[14]	ZHANG Y, PROENCA R, MAFFEI M，et al. Positional cloning of the mouse obese gene and its human homologue[J]. Nature，1994，372(6505):425-432. DOI：10.1038/372425a0.
[15]	KADOWAKI T, YAMAUCHI T, KUBOTA N，et al. Adiponectin and adiponectin receptors in insulin resistance，diabetes，and the metabolic syndrome[J]. J Clin Invest，2006，116(7):1784-1792. DOI：10.1172/JCI29126.
[16]	KADOWAKI T, YAMAUCHI T. Adiponectin and adiponectin receptors[J]. Endocr Rev，2005，26(3):439-451. DOI：10.1210/er.2005-0005.
[17]	DANIELE A, DE ROSA A, NIGRO E，et al. Adiponectin oligomerization state and adiponectin receptors airway expression in chronic obstructive pulmonary disease[J]. Int J Biochem Cell Biol，2012，44(3):563-569. DOI：10.1016/j.biocel.2011.12.016.
[18]	THYAGARAJAN B, JACOBS D R Jr, SMITH L J，et al. Serum adiponectin is positively associated with lung function in young adults，independent of obesity：the CARDIA study[J]. Respir Res，2010，11:176. DOI：10.1186/1465-9921-11-176.
[19]	NAKANISHI K, TAKEDA Y, TETSUMOTO S，et al. Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice：implications for therapy[J]. Am J Respir Crit Care Med，2011，183(9):1164-1175. DOI：10.1164/rccm.201007-1091OC.
[20]	SUN Y, AN N, LI J S，et al. miRNA-206 regulates human pulmonary microvascular endothelial cell apoptosis via targeting in chronic obstructive pulmonary disease[J]. J Cell Biochem，2019，120(4):6223-6236. DOI：10.1002/jcb.27910.
[21]	XIA S Y, QU J, JIA H，et al. Overexpression of Forkhead box C1 attenuates oxidative stress，inflammation and apoptosis in chronic obstructive pulmonary disease[J]. Life Sci，2019，216:75-84. DOI：10.1016/j.lfs.2018.11.023.
[22]	ZHOU X, YI D J, WU Y H，et al. Expression of diaphragmatic myostatin and correlation with apoptosis in rats with chronic obstructive pulmonary disease[J]. Exp Ther Med，2018，15(3):2295-2300. DOI：10.3892/etm.2018.5686.
[23]	JIANG M X, QI L, LI L S，et al. The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer[J]. Cell Death Discov，2020，6:112. DOI：10.1038/s41420-020-00349-0.
[24]	SARGOLZAEI J, CHAMANI E, KAZEMI T，et al. The role of adiponectin and adipolin as anti-inflammatory adipokines in the formation of macrophage foam cells and their association with cardiovascular diseases[J]. Clin Biochem，2018，54:1-10. DOI：10.1016/j.clinbiochem.2018.02.008.
[25]	WEI C Y, WANG Y M, HAN L，et al. Nitrate esters alleviated coronary atherosclerosis through inhibition of NF-κB-regulated macrophage polarization shift in epicardial adipose tissue[J]. J Cardiovasc Pharmacol，2020，75(5):475-482. DOI：10.1097/FJC.0000000000000818.
[26]	AJUWON K M, SPURLOCK M E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes[J]. Am J Physiol Regul Integr Comp Physiol，2005，288(5):R1220-1225. DOI：10.1152/ajpregu.00397.2004.
[27]	MAEDA N, SHIMOMURA I, KISHIDA K，et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30[J]. Nat Med，2002，8(7):731-737. DOI：10.1038/nm724.
[28]	HANSON C, RUTTEN E P, WOUTERS E F，et al. Influence of diet and obesity on COPD development and outcomes[J]. Int J Chron Obstruct Pulmon Dis，2014，9:723-733. DOI：10.2147/COPD.S50111.
[29]	CHEN H P, LI Z Y, DONG L L，et al. Lipid metabolism in chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis，2019，14:1009-1018. DOI：10.2147/COPD.S196210.
[30]	YOON M J, LEE G Y, CHUNG J J，et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase，p38 mitogen-activated protein kinase，and peroxisome proliferator-activated receptor alpha[J]. Diabetes，2006，55(9):2562-2570. DOI：10.2337/db05-1322.
[31]	TOMAS E, TSAO T S, SAHA A K，et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain：acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation[J]. Proc Natl Acad Sci USA，2002，99(25):16309-16313. DOI：10.1073/pnas.222657499.
[32]	YAMAUCHI T, NIO Y, MAKI T，et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions[J]. Nat Med，2007，13(3):332-339. DOI：10.1038/nm1557.
[33]	AWAZAWA M, UEKI K, INABE K，et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway[J]. Biochem Biophys Res Commun，2009，382(1):51-56. DOI：10.1016/j.bbrc.2009.02.131.
[34]	AHIMA R S, FLIER J S. Leptin[J]. Annu Rev Physiol，2000，62:413-437. DOI：10.1146/annurev.physiol.62.1.413.
[35]	MYERS M G, COWLEY M A, MÜNZBERG H. Mechanisms of leptin action and leptin resistance[J]. Annu Rev Physiol，2008，70:537-556. DOI：10.1146/annurev.physiol.70.113006.100707.
[36]	UZUN H, UYSAL P. Evaluation of ghrelin and leptin in chronic obstructive pulmonary disease[J]. Eurasian J Pulmonol，2019，21(2):114. DOI：10.4103/ejop.ejop_72_18.
[37]	HICKSON D A, BURCHFIEL C M, PETRINI M F，et al. Leptin is inversely associated with lung function in African Americans，independent of adiposity：the Jackson Heart Study[J]. Obesity （Silver Spring），2011，19(5):1054-1061. DOI：10.1038/oby.2010.240.
[38]	HANSEL N N, GAO L, RAFAELS N M，et al. Leptin receptor polymorphisms and lung function decline in COPD[J]. Eur Respir J，2009，34(1):103-110. DOI：10.1183/09031936.00120408.
[39]	PÉREZ-BAUTISTA O, MONTAÑO M, PÉREZ-PADILLA R，et al. Women with COPD by biomass show different serum profile of adipokines，incretins，and peptide hormones than smokers[J]. Respir Res，2018，19(1):239. DOI：10.1186/s12931-018-0943-4.
[40]	ZHOU L, YUAN C, ZHANG J Y，et al. Circulating leptin concentrations in patients with chronic obstructive pulmonary disease：a systematic review and meta-analysis[J]. Respiration，2013，86(6):512-522. DOI：10.1159/000354191.
[41]	WANG Z, HUANG X X, YE X K，et al. Roles of leptin on the key effector cells of rheumatoid arthritis[J]. Immunol Lett，2021，233:92-96. DOI：10.1016/j.imlet.2021.02.008.
[42]	KONTNY E, JANICKA I, SKALSKA U，et al. The effect of multimeric adiponectin isoforms and leptin on the function of rheumatoid fibroblast-like synoviocytes[J]. Scand J Rheumatol，2015，44(5):363-368. DOI：10.3109/03009742.2015.1025833.
[43]	SCOTECE M, CONDE J, LÓPEZ V，et al. Adiponectin and leptin：new targets in inflammation[J]. Basic Clin Pharmacol Toxicol，2014，114(1):97-102. DOI：10.1111/bcpt.12109.
[44]	LEIGUEZ E, MOTTA P, MAIA MARQUES R，et al. A representative GIIA phospholipase A2 activates preadipocytes to produce inflammatory mediators implicated in obesity development[J]. Biomolecules，2020，10(12):E1593. DOI：10.3390/biom10121593.
[45]	HSU P S, WU C S, CHANG J F，et al. Leptin promotes cPLA₂ gene expression through activation of the MAPK/NF-κB/p300 cascade[J]. Int J Mol Sci，2015，16(11):27640-27658. DOI：10.3390/ijms161126045.
[46]	UCHIDA K. A lipid-derived endogenous inducer of COX-2：a bridge between inflammation and oxidative stress[J]. Mol Cells，2008，25(3):347-351.
[47]	MÖGEL I, BAUMANN S, BÖHME A，et al. The aromatic volatile organic compounds toluene，benzene and styrene induce COX-2 and prostaglandins in human lung epithelial cells via oxidative stress and p38 MAPK activation[J]. Toxicology，2011，289(1):28-37. DOI：10.1016/j.tox.2011.07.006.
[48]	LIU Y X, LI Y Z, LIANG J T，et al. Leptin：an entry point for the treatment of peripheral tissue fibrosis and related diseases[J]. Int Immunopharmacol，2022，106:108608. DOI：10.1016/j.intimp.2022.108608.
[49]	HSU P S, LIN C M, CHANG J F，et al. Participation of NADPH oxidase-related reactive oxygen species in leptin-promoted pulmonary inflammation：regulation of cPLA₂α and COX-2 expression[J]. Int J Mol Sci，2019，20(5):1078. DOI：10.3390/ijms20051078.
[50]	BLANCA A J, RUIZ-ARMENTA M V, ZAMBRANO S，et al. Leptin induces oxidative stress through activation of NADPH oxidase in renal tubular cells：antioxidant effect of L-carnitine[J]. J Cell Biochem，2016，117(10):2281-2288. DOI：10.1002/jcb.25526.
[51]	SAMAL B, SUN Y, STEARNS G，et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor[J]. Mol Cell Biol，1994，14(2):1431-1437. DOI：10.1128/mcb.14.2.1431-1437.1994.
[52]	KEYHANMANESH R, ALIPOUR M R, EBRAHIMI H，et al. Effects of diet-induced obesity on tracheal responsiveness to methacholine，tracheal visfatin level，and lung histological changes in ovalbumin-sensitized female wistar rats[J]. Inflammation，2018，41(3):846-858. DOI：10.1007/s10753-018-0738-2.
[53]	STASTNY J, BIENERTOVA-VASKU J, VASKU A. Visfatin and its role in obesity development[J]. Diabetes Metab Syndr，2012，6(2):120-124. DOI：10.1016/j.dsx.2012.08.011.
[54]	PANG X X, ANSARI A R, YANG W J，et al. Visfatin regulates inflammatory mediators in mouse intestinal mucosa through toll-like receptors signaling under lipopolysaccharide stress[J]. Arch Immunol Ther Exp （Warsz），2021，69(1):11. DOI：10.1007/s00005-021-00611-y.
[55]	GOLDMANN T, ZISSEL G, WATZ H，et al. Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis[J]. Respir Res，2018，19(1):138. DOI：10.1186/s12931-018-0841-9.
[56]	HE J Y, CUI H J, TANG L J，et al. Inhibition of pre-B cell colony-enhancing factor attenuates inflammation induced by hyperoxia in EA.hy926 cells[J]. Int J Mol Med，2017，40(3):859-866. DOI：10.3892/ijmm.2017.3045.
[57]	WEDZICHA J A. Airway mucins in chronic obstructive pulmonary disease[J]. N Engl J Med，2017，377(10):986-987. DOI：10.1056/NEJMe1707210.
[58]	KIM S R, BAE Y H, BAE S K，et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells[J]. Biochim Biophys Acta，2008，1783(5):886-895. DOI：10.1016/j.bbamcr.2008.01.004.
[59]	ROMACHO T, VILLALOBOS L A, CERCAS E，et al. Visfatin as a novel mediator released by inflamed human endothelial cells[J]. PLoS One，2013，8(10):e78283. DOI：10.1371/journal.pone.0078283.
[60]	LEE W J, WU C S, LIN H，et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappa B pathway[J]. Int J Obes （Lond），2009，33(4):465-472. DOI：10.1038/ijo.2009.24.
[61]	CAROLAN B J, KIM Y I, WILLIAMS A A，et al. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med，2013，188(5):561-566. DOI：10.1164/rccm.201212-2299OC.
[62]	STOLL P, FOERSTER S, VIRCHOW J C，et al. Overweight is a predictor of long-term survival in hospitalised patients with exacerbations of COPD[J]. Respir Med，2016，116:59-62. DOI：10.1016/j.rmed.2016.05.016.
[63]	WANG Y D, LI Z, LI F S. Nonlinear relationship between visceral adiposity index and lung function：a population-based study[J]. Respir Res，2021，22(1):161. DOI：10.1186/s12931-021-01751-7.
[64]	HARMS C A. Does gender affect pulmonary function and exercise capacity？[J]. Respir Physiol Neurobiol，2006，151(2/3):124-131. DOI：10.1016/j.resp.2005.10.010.
[65]	DEMERATH E W, SUN S S, ROGERS N，et al. Anatomical patterning of visceral adipose tissue：race，sex，and age variation[J]. Obesity （Silver Spring），2007，15(12):2984-2993. DOI：10.1038/oby.2007.356.
[66]	ZHU J, ZHAO Z L, WU B，et al. Effect of body mass index on lung function in Chinese patients with chronic obstructive pulmonary disease：a multicenter cross-sectional study[J]. Int J Chron Obstruct Pulmon Dis，2020，15:2477-2486. DOI：10.2147/COPD.S265676.